ClinicalTrials.gg
CompletedNCT02973100Updated Sep 23, 2019Results posted

A Study of Investigational Dulaglutide Doses in Participants With Type 2 Diabetes on Metformin Monotherapy

A Phase 2 interventional study of Dulaglutide and Placebo in Type 2 Diabetes, sponsored by Eli Lilly and Company. Completed at 66 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-09-23.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
318
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 54 studies testing dulaglutide in Diabetes Mellitus, Type 2 — 3 open to participants now, 4 under way, 1 of them phase 3. dulaglutide · Diabetes Mellitus, Type 2.

Enrollment
20th of 54
318 · median 159
Started
2016
with 2 others
Phase 2
5 of 54
none open now
Registered
33rd of 54
by date
Lead sponsor
43 of 54
Eli Lilly and Company

Among the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2, this one is the 20th largest by enrollment, is one of 3 that started in 2016, is one of 5 in phase 2, and was the 33rd registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About dulaglutide

dulaglutide: first FDA approval 2014 (TRULICITY), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies testing dulaglutide in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of investigational doses of dulaglutide in participants with type 2 diabetes on metformin monotherapy.

03

Conditions studied

  • Type 2 Diabetes
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have had type 2 diabetes (T2D) for ≥6 months according to the World Health Organization (WHO) classification
  • Have of 7.0% to 10.0%, inclusive, as assessed by the central laboratory
  • Have been treated with stable doses of metformin for at least 3 months
  • Have a (BMI) ≥25 kilograms per square meter

Exclusion criteria

Exclusion Criteria:

  • Have type 1 diabetes (T1D)
  • Have used any glucose-lowering medication other than metformin 3 months prior to study entry or during screening/lead-in period or have used any glucagon-like peptide-1 receptor agonists (GLP-1 RAs) at any time in the past
  • Have had any of the following cardiovascular conditions: acute myocardial infarction (MI), Class III or Class IV heart failure, or cerebrovascular accident (stroke)
  • Have acute or chronic hepatitis, signs and symptoms of any other liver disease other than nonalcoholic fatty liver disease (NAFLD), or (ALT) level >2.5 times the upper limit of the reference range, as determined by the central laboratory at study entry; participants with NAFLD are eligible for participation in this trial
  • Have had chronic or acute pancreatitis any time prior to study entry
  • Have an estimated (eGFR) \<45 milliliters/minute/1.73 square meter, calculated by the Chronic Kidney Disease-Epidemiology (CKD-EPI) equation
  • Have serum calcitonin ≥20 picograms per milliliter, as determined by the central laboratory at study entry
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
318 participants (actual)

Study arms

  • Experimental
    Dulaglutide 4.5mg

    4.5mg of Dulaglutide administered subcutaneously (SC)

    Drug: Dulaglutide

  • Experimental
    Dulaglutide 3.0mg

    3.0mg of Dulaglutide administered SC

    Drug: Dulaglutide

  • Active comparator
    Dulaglutide 1.5mg

    1.5mg of Dulaglutide administered SC

    Drug: Dulaglutide

  • Placebo comparator
    Placebo

    Placebo administered SC

    Drug: Placebo

Interventions

  • Administered SC

    Also known as: LY2189265

  • DrugPlacebo

    Administered SC

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Hemoglobin A1c (HbA1c)

    HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time. Least Squares (LS) mean was determined by mixed-model repeated measures (MMRM) model with baseline as a covariate, pooled country, treatment, time, treatment\*time as fixed effects.

    Time frame: Baseline, Week 18

Secondary outcomes

  1. Percentage of Participants With HbA1c of <7.0%

    Hemoglobin A1c (HbA1c) is the glycosylated fraction of hemoglobin A. HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time.

    Time frame: Week 18

  2. Change From Baseline in Fasting Serum Glucose (FSG)

    Fasting serum glucose (FSG) is a test to determine how much glucose (sugar) is in a serum sample after an overnight fast. Least Squares (LS) means was determined by MMRM methodology with baseline as a covariate, pooled country, baseline HbA1c strata using \>=8% as cutoff, treatment, time, treatment\*time as fixed effects.

    Time frame: Baseline, Week 18

  3. Change From Baseline in Body Weight

    Least Squares (LS) mean was determined by mixed-model repeated measures (MMRM) model with baseline as a covariate, pooled country, baseline HbA1c strata using \>=8% as cutoff, treatment, time, treatment\*time as fixed effects.

    Time frame: Baseline, Week 18

  4. Percentage of Participants Discontinuing Study Drug Due to Adverse Events

    Adverse event (AE) defined as any unfavorable medical event, newly emerged or a deterioration of a preexisting condition, in other words any untoward medical occurrence in a patient administered a pharmaceutical product, without regard to the possibility of a causal relationship, that occurred after the visit for informed consent and up to the visit for completion of administration, or discontinuation.

    Time frame: Baseline through Week 18

  5. Rate of Documented Symptomatic Hypoglycemia

    Hypoglycemic events (HE) were classified as severe, documented symptomatic (defined as an HE with typical symptoms of hypoglycemia and a blood glucose level of ≤3.9 millimoles per liter \[mmol/L\]). Hypoglycemia rate per 30 days was summarized at each visit by treatment group. The rate of hypoglycemia was analyzed using a generalized estimation equations model with a negative binomial distribution and a Log link. LS mean was determined by MMRM methodology with baseline hypoglycemia rate, pooled country, HbA1c at Baseline, treatment, with log of exposure in days divided by 365.25 as the offset.

    Time frame: Week 18

  6. Pharmacokinetics (PK): The Maximum Drug Concentration at Steady State (Cmax,ss) of Dulaglutide

    Plasma samples for PK analysis were combined measure obtained from 0, 2, 4, 6, 10, 18, 22 weeks and until early termination of the visit. Cmax takes all time points post dose into account and one value was reported.

    Time frame: 0, 2, 4, 6, 10, 18, 22 weeks and early termination

  7. Pharmacokinetics: Area Under the Concentration-Time Curve at Steady State From Time Zero to 168 Hours (AUC[0-168], ss) of Dulaglutide

    AUC\[0-168h\] is a combined measure obtained from 0, 2, 4, 6, 10, 18, 22 weeks and until early termination of the visit.

    Time frame: 0, 2, 4, 6, 10, 18, 22 weeks and early termination

07

Results

Posted Aug 24, 2018

Participant flow

The study consisted of 3 periods: an approximately 2-week lead-in period, followed by an 18-week treatment period, and a 4-week safety follow-up period.

Participant flow — Overall Study
MilestonePlaceboDulaglutide 1.5 Milligrams (mg)Dulaglutide 3.0mgDulaglutide 4.5mg
Started82817976
Received at least 1 dose of study drug81817976
Completed75737569
Not completed7847
Withdrew: Adverse event1212
Withdrew: Lost to follow-up3110
Withdrew: Withdrawal by subject3514
Withdrew: Notification of change in address0001
Withdrew: Failed to attend safety followup period0010

Outcome measures

PrimaryChange From Baseline in Hemoglobin A1c (HbA1c)

HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time. Least Squares (LS) mean was determined by mixed-model repeated measures (MMRM) model with baseline as a covariate, pooled country, treatment, time, treatment\*time as fixed effects.

Time frame:
Baseline, Week 18
Reported as:
Least squares mean · Percentage of glycosylated hemoglobin
Change From Baseline in Hemoglobin A1c (HbA1c)
Percentage of glycosylated hemoglobinPlaceboDulaglutide 1.5mgDulaglutide 3.0mgDulaglutide 4.5mg
Change From Baseline in Hemoglobin A1c (HbA1c)-0.44 ± 0.101-1.23 ± 0.099-1.31 ± 0.099-1.40 ± 0.103
Statistical analysis
  • Placebo vs Dulaglutide 1.5mg · Mixed Models Analysis · p = <.001 · Mean difference (final values): -0.80 · 95% CI -1.07 to -0.53
  • Placebo vs Dulaglutide 3.0mg · Mixed Models Analysis · p = <0.001 · Mean difference (final values): -0.87 · 95% CI -1.14 to -0.60
  • Placebo vs Dulaglutide 4.5mg · Mixed Models Analysis · p = <.001 · Mean difference (final values): -0.96 · 95% CI -1.24 to -0.69
SecondaryPercentage of Participants With HbA1c of <7.0%

Hemoglobin A1c (HbA1c) is the glycosylated fraction of hemoglobin A. HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time.

Time frame:
Week 18
Reported as:
Number · Percentage of Participants
Percentage of Participants With HbA1c of <7.0%
Percentage of ParticipantsPlaceboDulaglutide 1.5mgDulaglutide 3.0mgDulaglutide 4.5mg
Percentage of Participants With HbA1c of <7.0%2071.271.268.2
Statistical analysis
  • Placebo vs Dulaglutide 1.5mg · Regression, Logistic · p = <.001 · Odds ratio (or): 24.489 · 95% CI 8.368 to 71.667
  • Placebo vs Dulaglutide 3.0mg · Regression, Logistic · p = <.001 · Odds ratio (or): 27.906 · 95% CI 9.238 to 84.300
  • Placebo vs Dulaglutide 4.5mg · Regression, Logistic · p = <.001 · Odds ratio (or): 21.852 · 95% CI 7.672 to 62.242
SecondaryChange From Baseline in Fasting Serum Glucose (FSG)

Fasting serum glucose (FSG) is a test to determine how much glucose (sugar) is in a serum sample after an overnight fast. Least Squares (LS) means was determined by MMRM methodology with baseline as a covariate, pooled country, baseline HbA1c strata using \>=8% as cutoff, treatment, time, treatment\*time as fixed effects.

Time frame:
Baseline, Week 18
Reported as:
Least squares mean · millimole/liter (mmol/L)
Change From Baseline in Fasting Serum Glucose (FSG)
millimole/liter (mmol/L)PlaceboDulaglutide 1.5mgDulaglutide 3.0mgDulaglutide 4.5mg
Change From Baseline in Fasting Serum Glucose (FSG)-0.69 ± 0.257-2.01 ± 0.261-1.92 ± 0.250-2.11 ± 0.263
Statistical analysis
  • Placebo vs Dulaglutide 1.5mg · Mixed Models Analysis · p = <0.001 · Mean difference (final values): -1.32 · 95% CI -2.02 to -0.62
  • Placebo vs Dulaglutide 3.0mg · Mixed Models Analysis · p = <0.001 · Mean difference (final values): -1.23 · 95% CI -1.91 to -0.54
  • Placebo vs Dulaglutide 4.5mg · Mixed Models Analysis · p = <0.001 · Mean difference (final values): -1.42 · 95% CI -2.12 to -0.72
SecondaryChange From Baseline in Body Weight

Least Squares (LS) mean was determined by mixed-model repeated measures (MMRM) model with baseline as a covariate, pooled country, baseline HbA1c strata using \>=8% as cutoff, treatment, time, treatment\*time as fixed effects.

Time frame:
Baseline, Week 18
Reported as:
Least squares mean · Kilograms (Kg)
Change From Baseline in Body Weight
Kilograms (Kg)PlaceboDulaglutide 1.5mgDulaglutide 3.0mgDulaglutide 4.5mg
Change From Baseline in Body Weight-1.6 ± 0.39-2.8 ± 0.39-3.9 ± 0.39-4.1 ± 0.41
Statistical analysis
  • Placebo vs Dulaglutide 1.5mg · Mixed Models Analysis · p = 0.025 · Mean difference (final values): -1.2 · 95% CI -2.3 to -0.2
  • Placebo vs Dulaglutide 3.0mg · Mixed Models Analysis · p = <0.001 · Mean difference (final values): -2.4 · 95% CI -3.4 to -1.3
  • Placebo vs Dulaglutide 4.5mg · Mixed Models Analysis · p = <0.001 · Mean difference (final values): -2.6 · 95% CI -3.7 to -1.5
SecondaryPercentage of Participants Discontinuing Study Drug Due to Adverse Events

Adverse event (AE) defined as any unfavorable medical event, newly emerged or a deterioration of a preexisting condition, in other words any untoward medical occurrence in a patient administered a pharmaceutical product, without regard to the possibility of a causal relationship, that occurred after the visit for informed consent and up to the visit for completion of administration, or discontinuation.

Time frame:
Baseline through Week 18
Reported as:
Number · Percentage of Participants
Percentage of Participants Discontinuing Study Drug Due to Adverse Events
Percentage of ParticipantsPlaceboDulaglutide 1.5mgDulaglutide 3.0mgDulaglutide 4.5mg
Percentage of Participants Discontinuing Study Drug Due to Adverse Events4.96.210.113.2
SecondaryRate of Documented Symptomatic Hypoglycemia

Hypoglycemic events (HE) were classified as severe, documented symptomatic (defined as an HE with typical symptoms of hypoglycemia and a blood glucose level of ≤3.9 millimoles per liter \[mmol/L\]). Hypoglycemia rate per 30 days was summarized at each visit by treatment group. The rate of hypoglycemia was analyzed using a generalized estimation equations model with a negative binomial distribution and a Log link. LS mean was determined by MMRM methodology with baseline hypoglycemia rate, pooled country, HbA1c at Baseline, treatment, with log of exposure in days divided by 365.25 as the offset.

Time frame:
Week 18
Reported as:
Least squares mean · Episodes/participant/365.25 days
Rate of Documented Symptomatic Hypoglycemia
Episodes/participant/365.25 daysPlaceboDulaglutide 1.5mgDulaglutide 3.0mgDulaglutide 4.5mg
Rate of Documented Symptomatic Hypoglycemia0.00 ± 0.0000.00 ± 0.0000.00 ± 0.0000.00 ± 0.001
SecondaryPharmacokinetics (PK): The Maximum Drug Concentration at Steady State (Cmax,ss) of Dulaglutide

Plasma samples for PK analysis were combined measure obtained from 0, 2, 4, 6, 10, 18, 22 weeks and until early termination of the visit. Cmax takes all time points post dose into account and one value was reported.

Time frame:
0, 2, 4, 6, 10, 18, 22 weeks and early termination
Reported as:
Mean · nanogram per milliliter (ng/mL)
Pharmacokinetics (PK): The Maximum Drug Concentration at Steady State (Cmax,ss) of Dulaglutide
nanogram per milliliter (ng/mL)Dulaglutide 1.5mgDulaglutide 3.0mgDulaglutide 4.5mg
Pharmacokinetics (PK): The Maximum Drug Concentration at Steady State (Cmax,ss) of Dulaglutide90.4 (38.9 to 170)151 (64.3 to 277)204 (87.2 to 377)
SecondaryPharmacokinetics: Area Under the Concentration-Time Curve at Steady State From Time Zero to 168 Hours (AUC[0-168], ss) of Dulaglutide

AUC\[0-168h\] is a combined measure obtained from 0, 2, 4, 6, 10, 18, 22 weeks and until early termination of the visit.

Time frame:
0, 2, 4, 6, 10, 18, 22 weeks and early termination
Reported as:
Mean · nanogram*hour per milliliter (ng*h/mL)
Pharmacokinetics: Area Under the Concentration-Time Curve at Steady State From Time Zero to 168 Hours (AUC[0-168], ss) of Dulaglutide
nanogram*hour per milliliter (ng*h/mL)Dulaglutide 1.5mgDulaglutide 3.0mgDulaglutide 4.5mg
Pharmacokinetics: Area Under the Concentration-Time Curve at Steady State From Time Zero to 168 Hours (AUC[0-168], ss) of Dulaglutide11800 (5300 to 21300)26700 (15300 to 41400)36600 (21100 to 56500)

Adverse events

Collected over Up to 22 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/81 (0%)4/81 (4.9%)29/81 (35.8%)
Dulaglutide 1.5mg0/81 (0%)3/81 (3.7%)36/81 (44.4%)
Dulaglutide 3.0mg0/79 (0%)7/79 (8.9%)49/79 (62%)
Dulaglutide 4.5mg0/76 (0%)3/76 (3.9%)39/76 (51.3%)
Most frequent serious events
Showing 10 of 23
Most frequent serious events
EventPlaceboDulaglutide 1.5mgDulaglutide 3.0mgDulaglutide 4.5mg
Abdominal pain upperGastrointestinal disorders0/810/810/791/76
PancreatitisGastrointestinal disorders0/810/810/791/76
CholecystitisHepatobiliary disorders0/810/810/791/76
Cholecystitis acuteHepatobiliary disorders0/810/810/791/76
BronchitisInfections and infestations0/810/810/791/76
Atrioventricular block second degreeCardiac disorders0/810/811/790/76
VomitingGastrointestinal disorders0/810/811/790/76
Cholecystitis infectiveInfections and infestations0/810/811/790/76
Fungal oesophagitisInfections and infestations0/810/811/790/76
Peritonsillar abscessInfections and infestations0/810/811/790/76
Most frequent other events
Showing 10 of 19
Most frequent other events
EventPlaceboDulaglutide 1.5mgDulaglutide 3.0mgDulaglutide 4.5mg
NauseaGastrointestinal disorders4/8118/8120/7923/76
DiarrhoeaGastrointestinal disorders9/819/8118/7916/76
Decreased appetiteMetabolism and nutrition disorders1/813/8113/796/76
VomitingGastrointestinal disorders4/819/819/7910/76
HeadacheNervous system disorders7/814/8110/795/76
DyspepsiaGastrointestinal disorders0/816/815/798/76
Abdominal painGastrointestinal disorders1/813/811/797/76
FatigueGeneral disorders2/811/814/797/76
ConstipationGastrointestinal disorders0/815/814/796/76
EructationGastrointestinal disorders0/813/811/796/76

Baseline characteristics

Age, Continuous
Age, Continuous(Years)PlaceboDulaglutide 1.5mgDulaglutide 3.0mgDulaglutide 4.5mgTotal
Mean56.52 ± 8.9357.65 ± 9.7955.90 ± 10.7457.13 ± 9.6356.80 ± 9.77
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboDulaglutide 1.5mgDulaglutide 3.0mgDulaglutide 4.5mgTotal
Female33424440159
Male48393536158
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboDulaglutide 1.5mgDulaglutide 3.0mgDulaglutide 4.5mgTotal
Hispanic or Latino35323830135
Not Hispanic or Latino46494045180
Unknown or Not Reported00112
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboDulaglutide 1.5mgDulaglutide 3.0mgDulaglutide 4.5mgTotal
American Indian or Alaska Native1069631
Asian00134
Native Hawaiian or Other Pacific Islander10001
Black or African American666624
White59685859244
More than one race514212
Unknown or Not Reported00101
Region of Enrollment
Region of Enrollment(Participants)PlaceboDulaglutide 1.5mgDulaglutide 3.0mgDulaglutide 4.5mgTotal
Romania665421
United States42454443174
Czechia10910837
Poland1311101044
Mexico1010101141
Baseline Hemoglobin A1c (HbA1c)
Baseline Hemoglobin A1c (HbA1c)(Percentage of glycosylated hemoglobin)PlaceboDulaglutide 1.5mgDulaglutide 3.0mgDulaglutide 4.5mgTotal
Mean8.08 ± 0.798.02 ± 0.808.16 ± 0.928.12 ± 0.818.09 ± 0.83
08

Study locations

66 sites
  • Parexel Early Phase Unit at Glendale
    Glendale, California 91206-4140, United States
  • Marin Endocrine Associates
    Greenbrae, California 94904, United States
  • National Research Institute
    Huntington Park, California 90255, United States
  • National Research Institute
    Los Angeles, California 90057, United States
  • Catalina Research Institute, LLC
    Montclair, California 91763, United States
  • Artemis Institute for Clinical Research
    San Diego, California 92103, United States
  • Encompass Clinical Research
    Spring Valley Lake, California 91978, United States
  • University Clinical Investigators, Inc.
    Tustin, California 92780, United States
  • Infosphere
    Van Nuys, California 91405, United States
  • Diablo Clinical Research
    Walnut Creek, California 94598, United States
  • Chase Medical Research, LLC
    Waterbury, Connecticut 06708, United States
  • Axes Medical Research, LLC
    Cooper City, Florida 33024, United States
  • Clinical Research of South Florida
    Coral Gables, Florida 33134, United States
  • East Coast Institute For Research
    Jacksonville, Florida 32204, United States
  • Suncoast Research Group, LLC
    Miami Lakes, Florida 33135, United States
  • New Horizon Research Center
    Miami, Florida 33175, United States
  • Palm Harbor Medical Associates
    Palm Harbor, Florida 34684, United States
  • In-Quest Medical Research, LLC - Norcross
    Norcross, Georgia 30071, United States
  • East West Medical Institute
    Honolulu, Hawaii 96814, United States
  • Elite Cilnical Trials LLLP
    Blackfoot, Idaho 83221, United States
  • Solaris Clinical Research
    Meridian, Idaho 83646, United States
  • HSHS Medical Group Diabetes Research
    Springfield, Illinois 62711, United States
  • American Health Network
    Indianapolis, Indiana 46254, United States
  • Iderc, P.L.C.
    Des Moines, Iowa 50314, United States
  • Cotton O'Neil Diabetes and Endocrinology Center
    Topeka, Kansas 66606, United States
  • ActivMed Practices & Research, Inc
    Methuen, Massachusetts 01844, United States
  • StudyMetrix Research, LLC
    Saint Peters, Missouri 63303, United States
  • Manhattan Medical Research
    New York Mills, New York 10016, United States
  • High Point Clinical Trials Center
    High Point, North Carolina 27265, United States
  • Aventiv Research
    Columbus, Ohio 43213, United States
  • The Corvallis Clinic P.C.
    Corvallis, Oregon 97330, United States
  • Heritage Valley Medical Group, Inc.
    Beaver, Pennsylvania 15009, United States
  • New Phase Research & Development
    Knoxville, Tennessee 37909, United States
  • Dallas Diabetes Endocrine Center
    Dallas, Texas 75230, United States
  • Consano Clinical Research
    San Antonio, Texas 78231, United States
  • Clinpoint Trial, LLC
    Waxahachie, Texas 75165, United States
  • Chrysalis Clinical Research
    Saint George, Utah 84790, United States
  • Rainier Clinical Research Center
    Renton, Washington 98057, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Brandýs Nad Labem-Stará Boleslav, 25001, Czechia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Krnov, 79401, Czechia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Praha 1, 11000, Czechia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Praha 4 - Krc, 140 59, Czechia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Praha 4, 149 00, Czechia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Praha 8, 181 00, Czechia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Chihuahua, 31217, Mexico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Cuernavaca, 62250, Mexico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Guadalajara, 04460, Mexico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Monterrey, 64460, Mexico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Tampico, 89000, Mexico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bialystok, 15-404, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bialystok, 15-445, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Gdansk, 80-546, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Lodz, 90-242, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Lublin, 20-333, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Lublin, 20-538, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Poznan, 61-655, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Poznan, 61-853, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Ruda Slaska, 41-709, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Szczecin, 70-506, Poland
  • Marginal Doctor's Center
    Manati, 00674, Puerto Rico
  • American Telemedicine Center
    San Juan, 00917, Puerto Rico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Alba Iulia, 510053, Romania
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Baia Mare, 430222, Romania
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Iasi, 700547, Romania
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Oradea, 410159, Romania
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Satu-Mare, 440055, Romania
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2016, a primary completion of Jul 2017 and a completion of Aug 2017. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2018, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 22, 2016
First posted
Nov 25, 2016
Start
Dec 2016
Primary completionActual
Jul 15, 2017
CompletionActual
Aug 14, 2017
Results first posted
Aug 24, 2018
Last update
Sep 23, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 23, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02973100
Responsible party
Sponsor
First posted
Nov 25, 2016
Start date
Dec 2016
Primary completion
Jul 15, 2017
Completion
Aug 14, 2017
Results posted
Aug 24, 2018
Last update
Sep 23, 2019

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dulaglutide

Start the discussion